ArticleInternational journal of pharmaceutics: X2025
Carrier-free multi-components self-delivery nanocomplex for tumor synergistic therapy.
Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the intricate nature of tumors, developing multidrug delivery system to enhance synergistic therapy for tumors is urgently needed. Herein, we present a carrier-free nanocomplex (DHT NC@SF MPN), consisting of dihydrotanshinone-1 nanocrystals (DHT NC) combined with silybin-ferric metal-phenolic network coatings (SF MPN), for multidrug self-delivery and chemo/chemodynamic synergistic cancer therapy. The generated nanocomplex (DHT NC@SF MPN) was completely composed of three therapeutic ingredients: DHT (56.08 %), Sil (41.88 %), and Fe(III) (2.01 %) without incorporation of any nano-materials. It displayed spherical core-shell structure with particle size 262 nm and acid responding drug release. The nanocomplex could be efficiently uptaken by HGC-27 tumor cells through the lipid raft/caveolin mediated pathway. It exhibited stronger tumor cell proliferation inhibition, migration inhibition, cell apoptosis and ferroptosis compared with free drugs. On tumor bearing mice, it showed comparable anti-tumor efficacy with the commercial paclitaxel liposome while systemic toxicity was negligible. Therefore, the facile nanocarrier-free multidrug self-delivery nanoplatform shed light on developing advanced nanomedicine for tumor synergistic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.